{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:59:07Z","timestamp":1784159947735,"version":"3.55.0"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"Suppl2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2022,10,4]]},"abstract":"<jats:p>The indiscriminate and massive antibiotic use in the clinical practice and in agriculture or cattle during the past few decades has produced a serious world health problem that entails high morbidity and mortality: the antibiotic multi-drug resistance. In 2017 and 2019, the World Health Organization published a list of urgent threats and priorities in the context of drug resistance, which only included Gram-negative bacteria and specially focused on carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, as well as carbapenem and third generation cephalosporin-resistant Enterobacteriaceae. This scenario emphasizes the need of developing and testing new antibiotics from different families, such as new beta-lactams, highlighting cefiderocol and its original mechanism of action; new beta-lactamase inhibitors, with vaborbactam or relebactam among others; new quinolones such as delafloxacin, and also omadacycline or eravacycline, as members of the tetracycline family. The present work reviews the importance and impact of Gram-negative bacterial infections and their resistance mechanisms, and analyzes the current therapeutic paradigm as well as the role of new antibiotics with a promising future in the era of multi and pan-drug resistance.<\/jats:p>","DOI":"10.37201\/req\/s02.01.2022","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T12:02:23Z","timestamp":1664884943000},"page":"1-15","source":"Crossref","is-referenced-by-count":19,"title":["Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives"],"prefix":"10.37201","volume":"35","author":[{"given":"V\u00edctor","family":"Garcia-Bustos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Dafne","family":"Caba\u00f1ero-Naval\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"23328","published-online":{"date-parts":[[2022,10,4]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":[],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T06:15:31Z","timestamp":1664950531000},"score":1,"resource":{"primary":{"URL":"https:\/\/seq.es\/abstract\/rev-esp-quimioter-202235suppl-21-15\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":0,"journal-issue":{"issue":"Suppl2","published-online":{"date-parts":[[2022,10,4]]},"published-print":{"date-parts":[[2022,10,4]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/s02.01.2022","relation":{},"ISSN":["0214-3429","1988-9518"],"issn-type":[{"value":"0214-3429","type":"print"},{"value":"1988-9518","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]}}}